Personalis, Inc, (NASDAQ: PSNL ) stock appears to be an entity at a pivotal stage where it could realise a dramatic turn in its usual operations. That turn is conditional and depends on whether its clinicalGamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track recor ...

Personalis (PSNL) has been beaten down lately with too much selling pressure. While the stock has lost 27.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of pric ...

Personalis (PSNL) has been on a downward spiral lately with significant selling pressure. After declining 30.5% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscil ...

Core Viewpoint - Personalis (PSNL) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - Changes in a company's future earnings potential, as indicated by earnings estimate revisions, are strongly correlated with near-term stock price movements [3]. - Institutional investors utilize earnings estimates to determine the fair value of a company's shares, leading to buying or selling actions that affect stock prices [3]. Company Performance and Outlook - The upgrade in rating for Personalis suggests an improvement in the company's underlying business, which should encourage investors to drive the stock price higher [4]. - The Zacks Consensus Estimate for Personalis has increased by 2.5% over the past three months, with expected earnings of -$0.98 per share for the fiscal year ending December 2025, indicating no year-over-year change [7]. Zacks Rating System - The Zacks Rank stock-rating system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [6]. - The Zacks rating system maintains a balanced distribution of "buy" and "sell" ratings, ensuring that only the top 20% of stocks receive a "Strong Buy" or "Buy" rating, indicating superior earnings estimate revisions [8][9].

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 100 points [1] - Super Micro Computer, Inc. reported fourth-quarter net sales of $5.76 billion, an increase from $4.6 billion in the third quarter and $5.4 billion in the same quarter last year [2] - Super Micro's net sales missed the Street consensus estimate of $5.88 billion, and earnings per share were $0.41, below the consensus estimate of $0.44 [2] Group 2 - Super Micro Computer shares fell 16.3% to $47.90 in pre-market trading following the earnings report [2] - LifeMD, Inc. saw a decline of 28.8% to $8.43 in pre-market trading after reporting worse-than-expected second-quarter EPS and sales [4] - Personalis, Inc. declined 26.1% to $4.17 in pre-market trading after missing second-quarter revenue and cutting FY25 sales guidance [4] - Evolus, Inc. fell 25.5% to $6.63 in pre-market trading after missing second-quarter estimates and lowering FY25 sales guidance [4] - Opendoor Technologies Inc. declined 18.5% to $2.05 in pre-market trading due to weak third-quarter sales guidance [4] - Digital Turbine, Inc. fell 18.2% to $4.45 in pre-market trading after reporting a first-quarter EPS miss [4] - Snap Inc. shares dropped 17.1% to $7.79 in pre-market trading following its second-quarter financial results [4] - Day One Biopharmaceuticals, Inc. fell 14.2% to $5.90 in pre-market trading after reporting worse-than-expected quarterly revenue [4] - Trivago NV – ADR declined 13.3% to $4.20 in pre-market trading after its quarterly results [4] - Hackett Group Inc. fell 13.3% to $19.75 in pre-market trading after issuing a weak third-quarter forecast [4] - Paysign Inc. dropped 11.5% to $6.30 in pre-market trading after reporting Q2 EPS below estimates [4] - The Mosaic Company fell 4.7% to $33.99 in pre-market trading following weak quarterly earnings [4]

Financial Data and Key Metrics Changes - Total company revenue for Q2 2025 was $17.2 million, a 24% decrease from $22.6 million in the same period last year [20] - Biopharma revenue was $11.1 million, down 16% from $13.2 million year-over-year, primarily due to project delays and a decline from Moderna [21] - Gross margin decreased to 27.6% from 35.6% year-over-year, impacted by lower revenue and unreimbursed clinical test costs [22] - Net loss for Q2 was $20.1 million compared to $12.8 million in the prior year [23] Business Line Data and Key Metrics Changes - Clinical revenue recognized was $500,000 from NEXT Dx and NEXT Personal Molecular tests, up from $100,000 year-over-year [21] - The number of clinical tests delivered in Q2 was 3,478, a 59% increase from Q1 and over 575% growth from the previous year [13] - The company expects to grow its MRD segment by 300% to 400% this year, with significant revenue contributions anticipated in Q4 [11] Market Data and Key Metrics Changes - The minimal residual disease (MRD) market is projected to exceed $20 billion annually, with Personalis positioned to capture a significant share [7] - The company is actively pursuing Medicare coverage for two indications by the end of the year, which is expected to unlock a significant revenue stream [12] Company Strategy and Development Direction - The company is focused on accelerating clinical adoption through partnerships, particularly with Tempus, and expanding its base of ordering physicians [6][13] - A three-point action plan is in place to pursue the high end of the revised revenue guidance, focusing on biopharma pipeline conversion, clinical momentum, and reimbursement advancements [10] - The company aims to achieve Medicare reimbursement for two indications this year, which is seen as a pivotal catalyst for growth [12] Management's Comments on Operating Environment and Future Outlook - Management acknowledged industry-wide headwinds in biopharma R&D spending and political changes affecting customer projects, leading to revenue shifts [9] - The company remains confident in its MRD technology's demand and is actively managing its near-term challenges [10] - Management expressed optimism about the clinical adoption of its technology and the potential for significant revenue growth post-reimbursement [18] Other Important Information - The company ended Q2 with $173.2 million in cash and short-term investments, with no debt other than minor equipment loans [24] - Cash usage for operations and capital equipment additions in Q2 was $13.2 million, with an expected total cash usage of approximately $75 million for the full year [25] Q&A Session Summary Question: Rationale for lowering clinical revenue guidance - Management explained that the guidance was narrowed due to the timing of reimbursement and expected to achieve reimbursement for one indication in Q3 and another in Q4 [30][31] Question: Early use cases and physician engagement - Management highlighted that the technology is being used effectively in breast cancer, lung cancer, and immunotherapy monitoring, with high retention rates among physicians [34][36] Question: Cash flow and future funding needs - Management confirmed that the current cash position is sufficient to reach cash flow breakeven without needing to raise additional funds [40][41] Question: Impact of policy headwinds on biopharma customers - Management noted that project delays are expected to convert to revenue in the next two to four quarters, with strong growth in the MRD offering [72] Question: Differentiation of NextPersonal in the competitive landscape - Management emphasized the strength of their clinical evidence and ongoing investments in evidence development to support reimbursement applications [75] Question: Conversations at ASCO and future implementation - Management reported positive feedback from ASCO, reinforcing the predictive capabilities of their tests and plans to expand reimbursement applications [84][86]

Financial and Business Highlights [Q2 2025 Financial Performance](index=1&type=section&id=Q2_2025_Financial_Performance) Personalis reported Q2 2025 revenue of $17.2 million, a 24% decrease year-over-year, with net loss widening to $20.1 million Q2 2025 Key Financial Metrics (vs. Q2 2024) | Metric | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $17.2M | $22.6M | -24% | | Gross Margin | 27.6% | 35.6% | -8.0 p.p. | | Net Loss | $20.1M | $12.8M | +57% | | Net Loss Per Share | $0.23 | $0.24 | N/A | | Cash & Investments | $173.2M | - | - | - The year-over-year revenue decrease was primarily driven by a **$5.6 million** decline from Natera and a **$2.1 million** decrease from pharma tests and other customers, partially offset by a **$2.0 million** increase in population sequencing revenue[4](index=4&type=chunk) - Cash, cash equivalents, and short-term investments totaled **$173.2 million** as of June 30, 2025, with **$13.2 million** used in cash from operations and capital expenditures during the quarter[7](index=7&type=chunk) [Strategic and Operational Highlights](index=1&type=section&id=Strategic_and_Operational_Highlights) The company achieved significant strategic milestones, including 59% sequential growth in clinical test volume and expanded partnership with Tempus AI for colorectal cancer - Clinical test volume grew **59%** sequentially, with **3,478** tests delivered in Q2 2025, indicating accelerating adoption of the NeXT Personal® platform[1](index=1&type=chunk)[2](index=2&type=chunk)[3](index=3&type=chunk) - The strategic collaboration with Tempus AI was expanded to include commercialization for colorectal cancer, a major new indication[3](index=3&type=chunk) - Pivotal data presented at the 2025 ASCO Annual Meeting demonstrated NeXT Personal's ability to predict therapy response and detect cancer progression up to **16 months** earlier than standard imaging[3](index=3&type=chunk) Financial Outlook [Q3 2025 Guidance](index=2&type=section&id=Q3_2025_Guidance) For Q3 2025, Personalis anticipates total revenue between $12.0 million and $14.0 million, with pharma tests contributing $11.0 to $13.0 million Q3 2025 Financial Guidance | Metric | Guidance Range | | :--- | :--- | | Total Company Revenue | $12.0M - $14.0M | | Revenue from Pharma & Other | $11.0M - $13.0M | | Revenue from Pop Sequencing & Enterprise | ~$1.0M | [Full Year 2025 Guidance](index=2&type=section&id=Full_Year_2025_Guidance) Personalis revised full-year 2025 revenue guidance to **$70-$80 million**, increasing expected net loss to **$85 million** and cash usage to **$75 million** Updated Full Year 2025 Guidance | Metric | Updated 2025 Guidance | Previous 2025 Guidance | | :--- | :--- | :--- | | Total Revenue | $70M - $80M | $80M - $90M | | Pharma & Other Revenue | $52M - $58M | $62M - $64M | | Clinical Tests Revenue | $3M - $6M | $3M - $10M | | Gross Margin | 22% - 24% | N/A | | Net Loss | ~$85M | ~$83M | | Cash Usage | ~$75M | N/A | - The reduction in revenue guidance for pharma tests and services is attributed to variability with biopharma projects and the timing of sample receipts[7](index=7&type=chunk) - Increased cash usage of approximately **$75 million** is planned to fund investments in the "Win-in-MRD" strategy, including growing test volume and expanding clinical evidence generation[7](index=7&type=chunk) Consolidated Financial Statements [Consolidated Statements of Operations](index=4&type=section&id=Consolidated_Statements_of_Operations) For Q2 2025, Personalis reported a net loss of **$20.1 million** on revenues of **$17.2 million**, with loss from operations widening to **$21.8 million** Statement of Operations Summary (Three Months Ended June 30) | (In thousands) | 2025 | 2024 | | :--- | :--- | :--- | | Revenue | $17,203 | $22,580 | | Cost of revenue | $12,447 | $14,543 | | R&D | $12,381 | $12,957 | | SG&A | $14,179 | $11,973 | | Loss from operations | $(21,804) | $(16,893) | | Net loss | $(20,056) | $(12,802) | | Net loss per share | $(0.23) | $(0.24) | - For the six months ended June 30, 2025, the net loss was **$35.8 million**, compared to a net loss of **$25.8 million** for the same period in 2024[11](index=11&type=chunk) [Supplemental Revenue Information](index=5&type=section&id=Supplemental_Revenue_Information) In Q2 2025, Pharma tests and services led revenue at **$11.0 million** (-16% YoY), while population sequencing grew **158%** to **$3.3 million** Revenue by Source (Three Months Ended June 30) | (In thousands) | 2025 | 2024 | Change (YoY) | | :--- | :--- | :--- | :--- | | Pharma tests and services | $11,023 | $13,197 | -16% | | Enterprise sales | $2,315 | $7,958 | -71% | | Population sequencing | $3,308 | $1,280 | +158% | | Clinical diagnostic | $469 | $117 | +301% | | Total revenue | $17,203 | $22,580 | -24% | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated_Balance_Sheets) As of June 30, 2025, Personalis reported total assets of **$258.7 million** and maintained **$173.2 million** in cash and investments Balance Sheet Summary | (In thousands) | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash, cash equivalents & short-term investments | $173,232 | $185,009 | | Total current assets | $193,343 | $203,015 | | Total assets | $258,680 | $270,268 | | Total current liabilities | $31,723 | $31,126 | | Total liabilities | $67,851 | $67,311 | | Total stockholders' equity | $190,829 | $202,957 |

PART I — FINANCIAL INFORMATION [Financial Statements](index=7&type=section&id=Item%201.%20Financial%20Statements) This section presents Personalis, Inc.'s unaudited consolidated financial statements for the quarter and six months ended June 30, 2025, including balance sheets, income statements, and cash flows [Consolidated Balance Sheets](index=7&type=section&id=Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to $258.7 million from $270.3 million, primarily due to lower cash, while liabilities remained stable and equity decreased to $190.8 million Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $53,374 | $91,415 | | Total current assets | $193,343 | $203,015 | | Total assets | $258,680 | $270,268 | | Total current liabilities | $31,723 | $31,126 | | Total liabilities | $67,851 | $67,311 | | Total stockholders' equity | $190,829 | $202,957 | [Consolidated Statements of Operations](index=8&type=section&id=Consolidated%20Statements%20of%20Operations) For Q2 2025, revenue decreased 23.8% to $17.2 million, and net loss widened to $20.1 million, with similar trends for the six-month period Statement of Operations Summary (in thousands) | Metric | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Revenue | $17,203 | $22,580 | $37,808 | $42,105 | | Loss from operations | $(21,804) | $(16,893) | $(39,500) | $(35,773) | | Net loss | $(20,056) | $(12,802) | $(35,806) | $(25,770) | | Net loss per share | $(0.23) | $(0.24) | $(0.41) | $(0.50) | [Consolidated Statements of Cash Flows](index=12&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operating activities for the six months ended June 30, 2025, was $30.9 million, while investing activities used $26.9 million, and financing activities provided $19.8 million Cash Flow Summary for Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(30,896) | $(31,156) | | Net cash (used in) provided by investing activities | $(26,913) | $19,294 | | Net cash provided by financing activities | $19,760 | $2,645 | | **Net change in cash** | **$(38,041)** | **$(9,237)** | [Notes to Consolidated Financial Statements](index=13&type=section&id=Notes%20to%20Consolidated%20Financial%20Statements) The notes detail accounting policies, revenue recognition, and significant agreements, including customer concentrations and transactions with Tempus and Merck - The company has significant customer concentration. For the six months ended June 30, 2025, Moderna, VA MVP, and Natera accounted for **28%**, **20%**, and **13%** of total revenue, respectively[65](index=65&type=chunk)[146](index=146&type=chunk) Revenue by Customer Type (in thousands) | Customer Type | Q2 2025 | Q2 2024 | Six Months 2025 | Six Months 2024 | | :--- | :--- | :--- | :--- | :--- | | Pharma tests and services | $11,023 | $13,197 | $24,617 | $23,009 | | Enterprise sales | $2,315 | $7,958 | $4,780 | $15,930 | | Population sequencing | $3,308 | $1,280 | $7,521 | $2,780 | | Clinical diagnostic | $469 | $117 | $777 | $312 | | Other | $88 | $28 | $113 | $74 | | **Total revenue** | **$17,203** | **$22,580** | **$37,808** | **$42,105** | - In December 2024, the company entered into an investment agreement with Merck, selling **14,044,943 shares** for **$50.0 million**. **$10.0 million** of the proceeds are reserved for opening a new ISO-certified lab outside the U.S.[103](index=103&type=chunk) - The company's agreement with Tempus involves Tempus marketing the NeXT Personal Dx test. Personalis compensates Tempus on a per-test basis and for promotional services. As of June 30, 2025, Personalis had received **$5.0 million** of a **$6.0 million** Market Development Fee from Tempus[91](index=91&type=chunk)[92](index=92&type=chunk)[102](index=102&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=29&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses Q2 and H1 2025 financial results, highlighting revenue decline, operating expense fluctuations, liquidity, and strategic initiatives like NeXT Personal adoption [Results of Operations](index=32&type=section&id=Results%20of%20Operations) Q2 2025 revenue decreased 24% year-over-year due to a 71% drop in Enterprise sales, partially offset by growth in Population sequencing and Clinical diagnostic revenue, while SG&A expenses increased 18% Q2 2025 vs Q2 2024 Revenue Change by Customer Type | Customer Type | Change | | :--- | :--- | | Pharma tests and services | (16%) | | Enterprise sales | (71%) | | Population sequencing | 158% | | Clinical diagnostic | 301% | | **Total revenue** | **(24%)** | - The decrease in Enterprise sales was mainly due to a **74% decrease** in the number of samples processed for Natera in Q2 2025 compared to Q2 2024. The company does not expect a long-term commercial relationship with Natera beyond 2025[147](index=147&type=chunk)[148](index=148&type=chunk) - The increase in SG&A expenses was primarily due to a **$1.4 million increase** in marketing activities for NeXT Personal Dx, including trade show expenses and Tempus' sales & marketing fees[158](index=158&type=chunk)[159](index=159&type=chunk) - Other income in 2024 included a significant noncash gain of **$3.0 million** for Q2 and **$7.7 million** for the six months from the remeasurement of Tempus Warrants, which was not present in 2025, contributing to the higher net loss in 2025[163](index=163&type=chunk) [Liquidity and Capital Resources](index=35&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held $173.2 million in cash and investments, deemed sufficient for the next 12 months, with financing activities providing $19.8 million from the ATM facility - The company had **$173.2 million** in cash, cash equivalents, and short-term investments as of June 30, 2025, and believes this is sufficient to fund operations for at least the next 12 months[164](index=164&type=chunk)[165](index=165&type=chunk) - For the six months ended June 30, 2025, financing activities provided **$19.8 million** in cash, largely due to **$17.8 million** in net proceeds from sales of common stock under the ATM facility[61](index=61&type=chunk)[168](index=168&type=chunk)[170](index=170&type=chunk) - Material cash requirements include capital expenditures expected to be approximately **$7.0 million** in 2025 and **$13.0-$14.0 million** annually in 2026 and 2027 to expand NeXT Personal Dx capacity[174](index=174&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) As a "smaller reporting company," Personalis is not required to provide the information requested under this item - The company is exempt from this disclosure requirement due to its status as a "smaller reporting company"[181](index=181&type=chunk) [Controls and Procedures](index=39&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that the company's disclosure controls and procedures were effective as of June 30, 2025, with no material changes in internal control over financial reporting - The CEO and CFO concluded that as of June 30, 2025, the company's disclosure controls and procedures were effective[182](index=182&type=chunk) - No changes in internal control over financial reporting occurred during the latest fiscal quarter that materially affected, or are reasonably likely to materially affect, internal controls[183](index=183&type=chunk) PART II — OTHER INFORMATION [Legal Proceedings](index=40&type=section&id=Item%201.%20Legal%20Proceedings) The company is not involved in any material legal proceedings as of June 30, 2025, and any ordinary course claims are not considered material - As of June 30, 2025, the Company was not involved in any material legal proceedings[119](index=119&type=chunk)[186](index=186&type=chunk) [Risk Factors](index=40&type=section&id=Item%201A.%20Risk%20Factors) This section details significant risks, including financial losses, customer concentration, operational dependencies, regulatory changes, cybersecurity threats, and intellectual property litigation [Operational, Strategic and Business Risks](index=40&type=section&id=Operational%20Strategic%20and%20Business%20Risks) The company faces operational risks from a history of net losses, substantial customer concentration, reliance on a single facility, and dependence on sole-source suppliers like Illumina - The company has a history of losses, with a net loss of **$35.8 million** for the six months ended June 30, 2025, and an accumulated deficit of **$585.8 million**[188](index=188&type=chunk) - The company has substantial customer concentration, with its top five customers accounting for **72%** of revenue for the six months ended June 30, 2025. It does not expect a long-term commercial relationship with Natera beyond 2025[198](index=198&type=chunk)[199](index=199&type=chunk)[200](index=200&type=chunk) - The company relies on Illumina as its sole supplier for sequencers and associated reagents, and any disruption could negatively impact laboratory operations[214](index=214&type=chunk) [Regulatory, Legal and Cybersecurity Risks](index=61&type=section&id=Regulatory%20Legal%20and%20Cybersecurity%20Risks) The company faces risks from potential FDA regulation of its Laboratory Developed Tests, complex data privacy laws, and significant cybersecurity threats that could lead to regulatory action and reputational harm - The company's tests are marketed as LDTs, but if the FDA determines they are subject to enforcement as medical devices, it could incur substantial costs and time delays for premarket clearance or approval[257](index=257&type=chunk)[261](index=261&type=chunk) - The company is subject to numerous evolving data privacy and security laws in the U.S. (HIPAA, CCPA) and abroad (GDPR), and failure to comply could result in significant fines, litigation, and business disruptions[295](index=295&type=chunk)[296](index=296&type=chunk)[298](index=298&type=chunk) - The company faces threats from cyberattacks, including ransomware, which could compromise sensitive data (PHI, genomic information) and lead to regulatory investigations, fines, and reputational harm[281](index=281&type=chunk)[282](index=282&type=chunk)[283](index=283&type=chunk) [Intellectual Property Risks](index=87&type=section&id=Intellectual%20Property%20Risks) The company's success depends on protecting its intellectual property and avoiding infringement in a litigious industry, facing uncertainty regarding patentability of genetic tests and risks of costly litigation - The company operates in an industry with extensive intellectual property litigation. A lawsuit, regardless of merit, could be costly and prevent the company from selling its tests[332](index=332&type=chunk)[333](index=333&type=chunk) - Recent court decisions have created uncertainty about the patentability of inventions related to natural phenomena, which could affect the company's ability to protect its diagnostic tests[341](index=341&type=chunk) - The company has been involved in legal proceedings to enforce its IP rights, such as a past complaint against Foresight for patent infringement, and two of its patents were recently invalidated in inter partes reviews initiated by Foresight[351](index=351&type=chunk)[353](index=353&type=chunk) [Financial and Market Risks and Risks Related to Owning Our Common Stock](index=99&type=section&id=Financial%20and%20Market%20Risks%20and%20Risks%20Related%20to%20Owning%20Our%20Common%20Stock) The company may need to raise additional capital, which could be dilutive, and its stock price is subject to volatility influenced by operating results and market conditions, with significant insider control - The company may need to raise additional capital, and its ability to do so could be impacted by worsening global economic conditions, potentially leading to operational cutbacks if funding is not secured[370](index=370&type=chunk)[372](index=372&type=chunk) - The market price of the common stock is volatile and can be influenced by fluctuating operating results, competition, regulatory changes, and general market conditions[373](index=373&type=chunk) - Insiders and holders of more than **5%** of the common stock may exercise significant control over the company, including the election of directors and approval of major corporate transactions[385](index=385&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=110&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) There were no unregistered sales of equity securities during the period - None[412](index=412&type=chunk) [Other Information](index=110&type=section&id=Item%205.%20Other%20Information) There are no disclosures required under this item for the reporting period - There are no disclosures required by this Item 5[414](index=414&type=chunk) [Exhibits](index=111&type=section&id=Item%206.%20Exhibits) This section lists the exhibits filed with the Quarterly Report on Form 10-Q, including certifications by the Principal Executive Officer and Principal Financial Officer, and the Inline XBRL documents - The report includes filed exhibits such as the 2020 Inducement Plan, CEO/CFO certifications (Sections 302 and 906), and Inline XBRL data[415](index=415&type=chunk)

Company Overview - Personalis (PSNL) shares increased by 14.2% to $7.51 in the last trading session, with a notable trading volume, and have gained 34.6% over the past four weeks, indicating positive investor sentiment towards the company's revenue growth from pharma tests and services [1][2] Financial Performance - The upcoming quarterly report for Personalis is expected to show a loss of $0.25 per share, reflecting a year-over-year decline of 4.2%, with revenues projected at $20.2 million, down 10.5% from the same quarter last year [2] - The consensus EPS estimate for Personalis has remained unchanged over the last 30 days, suggesting that stock price movements may not sustain without trends in earnings estimate revisions [3] Industry Context - Personalis operates within the Zacks Medical - Generic Drugs industry, which includes Taysha Gene Therapies, Inc. (TSHA), whose stock rose by 3.9% to $2.43 but has seen a decline of 15.8% over the past month [4] - Taysha Gene Therapies' consensus EPS estimate has increased by 12% over the past month to -$0.07, representing a year-over-year change of 22.2% [5]

Company Overview - Personalis (PSNL) shares increased by 7.3% to close at $6.45, with a notable trading volume compared to typical sessions, and a total gain of 21.4% over the past four weeks [1] - The positive investor sentiment is linked to the anticipated growth in revenues from Personalis' pharmaceutical tests and services, indicating a rising adoption of its technology [1] Financial Performance - Personalis is expected to report a quarterly loss of $0.25 per share, reflecting a year-over-year decline of 4.2%, with revenues projected at $20.2 million, down 10.5% from the same quarter last year [2] - The consensus EPS estimate for Personalis has been revised 2% higher in the last 30 days, suggesting a potential for price appreciation [3] Industry Context - Personalis operates within the Zacks Medical - Generic Drugs industry, where Doctor Reddy's (RDY) closed 0.5% lower at $15.72, with a 9.4% return over the past month [4] - Doctor Reddy's EPS estimate for the upcoming report remains unchanged at $0.19, representing a 5% decline compared to the previous year, and it also holds a Zacks Rank of 3 (Hold) [5]